Aethlon Medical, Inc. (NASDAQ:AEMD – Get Free Report) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totaling 32,925 shares, a decrease of 56.4% from the September 30th total of 75,446 shares. Based on an average daily volume of 57,317 shares, the short-interest ratio is presently 0.6 days. Approximately 4.7% of the company’s stock are short sold.
Aethlon Medical Price Performance
Shares of Aethlon Medical stock traded down $0.26 on Friday, reaching $5.26. 6,744 shares of the company traded hands, compared to its average volume of 829,991. Aethlon Medical has a 52 week low of $1.41 and a 52 week high of $26.90. The company has a 50 day moving average of $4.42 and a 200 day moving average of $7.82. The firm has a market capitalization of $3.74 million, a PE ratio of -0.15 and a beta of 1.21.
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.92) by ($0.10). As a group, analysts anticipate that Aethlon Medical will post -5.74 earnings per share for the current year.
Analyst Upgrades and Downgrades
AEMD has been the subject of several analyst reports. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a research note on Saturday, October 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Aethlon Medical in a research note on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Aethlon Medical in a report on Friday, September 18th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Aethlon Medical presently has an average rating of “Reduce” and an average target price of $1.50.
Aethlon Medical Company Profile
Aethlon Medical, Inc is a biotechnology and medical-device company focused on developing extracorporeal blood filtration technologies for life-threatening diseases. The company’s lead product candidate, the Hemopurifier, is designed to selectively remove harmful substances from the bloodstream, including cancer-promoting exosomes and certain viral particles.
The Hemopurifier is intended to be used with standard dialysis or blood-circulation equipment and is being investigated for potential applications in oncology and infectious disease.
Further Reading
- Five stocks we like better than Aethlon Medical
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
- Silicon Shock: Intel’s 25% Valuation Reset
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
